THERAPY DOSSIER · th-3378893c6ba6

Bifidobacterium breve NCC2950 (probiotic); altered Schaedler flora colonisation

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22162005 ↗2011Reported benefit

Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice.

MouseChemical/toxinNod1(-/-); Nod2(-/-) on C57BL/6 background, specific pathogen-free and gnotobiotic altered Schaedler flora; Nod1(+/-); Nod2(+/-) littermate controlsMale and femaleOral gavage10^9 colony-forming units of B. breve per gavageDaily for 14 days before colitis induction

Model: Acute experimental colitis induced by dextran sodium sulfate

Nod1(-/-); Nod2(-/-) mice had increased paracellular permeability, decreased E-cadherin and lower colonic RegIII-gamma than littermate controls with greater colitis susceptibility. Altered Schaedler flora colonisation or B. breve NCC2950 supplementation normalised RegIII-gamma expression and reduce…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…